• LAST PRICE
    3.5550
  • TODAY'S CHANGE (%)
    Trending Down-0.1050 (-2.8689%)
  • Bid / Lots
    3.5500/ 10
  • Ask / Lots
    3.5600/ 28
  • Open / Previous Close
    3.7000 / 3.6600
  • Day Range
    Low 3.5000
    High 3.7000
  • 52 Week Range
    Low 3.4000
    High 11.6900
  • Volume
    1,221,755
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 3.66
TimeVolumeEDIT
09:32 ET145463.635
09:34 ET127783.63
09:36 ET41773.6265
09:38 ET23943.635
09:39 ET110893.635
09:41 ET49813.635
09:43 ET132963.655
09:45 ET52033.655
09:48 ET26053.675
09:50 ET50443.675
09:52 ET312713.67
09:54 ET138403.645
09:56 ET37163.64
09:57 ET24903.64
09:59 ET68973.62
10:01 ET38003.615
10:03 ET106193.615
10:06 ET50493.605
10:08 ET61493.61
10:10 ET71013.61
10:12 ET239803.595
10:14 ET37533.6099
10:15 ET70343.59
10:17 ET42893.59
10:19 ET102983.59
10:21 ET22523.5899
10:24 ET316413.58
10:26 ET378963.5899
10:28 ET29813.57
10:30 ET30873.56
10:32 ET57993.565
10:33 ET75433.58
10:35 ET102983.565
10:37 ET19603.56
10:39 ET34603.56
10:42 ET147203.555
10:44 ET220893.55
10:46 ET63473.555
10:48 ET64923.56
10:50 ET135613.57
10:51 ET189443.565
10:53 ET184663.565
10:55 ET267973.57
10:57 ET84883.58
11:00 ET126353.575
11:02 ET53983.56
11:04 ET36003.55
11:06 ET11033.5589
11:08 ET64943.555
11:09 ET45763.555
11:11 ET137363.56
11:13 ET16003.5611
11:15 ET14753.56
11:18 ET120213.56
11:20 ET86623.5505
11:22 ET27643.5567
11:24 ET34193.53
11:26 ET90673.535
11:27 ET97493.54
11:29 ET62533.535
11:31 ET323783.55
11:33 ET59593.555
11:36 ET19343.555
11:38 ET12003.555
11:40 ET64003.555
11:42 ET43163.565
11:44 ET48363.565
11:45 ET38733.565
11:47 ET12573.565
11:49 ET48653.565
11:51 ET127793.565
11:54 ET22553.575
11:56 ET72053.585
11:58 ET20973.585
12:00 ET65363.565
12:02 ET20393.56
12:03 ET41373.5612
12:05 ET68813.5583
12:07 ET4003.555
12:09 ET10003.55
12:12 ET33303.535
12:14 ET148323.5412
12:16 ET21843.535
12:18 ET41953.524
12:20 ET16933.53
12:21 ET4003.52
12:23 ET94133.535
12:25 ET76963.5299
12:27 ET74943.52
12:30 ET112943.535
12:32 ET11343.535
12:34 ET155573.535
12:36 ET30923.535
12:38 ET86833.52
12:39 ET126503.515
12:41 ET221623.52
12:43 ET34373.515
12:45 ET5003.5112
12:48 ET172113.515
12:50 ET40783.5189
12:52 ET27503.51
12:54 ET75883.515
12:56 ET81763.52
12:57 ET80083.52
12:59 ET47953.515
01:01 ET66553.515
01:03 ET30473.515
01:06 ET21463.5112
01:08 ET5503.52
01:10 ET95813.5101
01:12 ET110493.515
01:14 ET355733.51
01:15 ET32153.51
01:17 ET17243.51
01:19 ET10913.515
01:21 ET22403.515
01:24 ET22003.51
01:26 ET117423.52
01:28 ET39143.525
01:30 ET19293.52
01:32 ET75853.515
01:33 ET8723.5188
01:35 ET178593.53
01:37 ET71593.52
01:39 ET2003.525
01:42 ET121003.535
01:44 ET230443.535
01:46 ET13763.53
01:48 ET49373.535
01:50 ET80313.5436
01:51 ET21303.5409
01:53 ET26893.54
01:55 ET124063.55
01:57 ET9003.55
02:00 ET82493.55
02:02 ET39863.55
02:04 ET76003.56
02:06 ET62223.555
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesEDIT
Editas Medicine Inc
301.9M
-1.5x
---
United StatesPSNL
Personalis Inc
287.2M
-2.9x
---
United StatesCDXC
Chromadex Corp
284.0M
-208.3x
---
United StatesADCT
ADC Therapeutics SA
297.7M
-1.2x
---
United StatesENTA
Enanta Pharmaceuticals Inc
233.1M
-2.0x
---
United StatesPSTX
Poseida Therapeutics Inc
300.1M
-2.6x
---
As of 2024-09-24

Company Information

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Contact Information

Headquarters
11 Hurley StCAMBRIDGE, MA, United States 02141-2110
Phone
617-401-9000
Fax
302-655-5049

Executives

Independent Chairman of the Board
Emma Reeve
President, Chief Executive Officer, Director
Gilmore O'Neill
Chief Financial Officer, Executive Vice President
Erick Lucera
Executive Vice President, Chief Scientific Officer
Linda Burkly
Senior Vice President, Chief Medical Officer
Baisong Mei

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$301.9M
Revenue (TTM)
$67.0M
Shares Outstanding
82.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.99
EPS
$-2.36
Book Value
$4.27
P/E Ratio
-1.5x
Price/Sales (TTM)
4.5
Price/Cash Flow (TTM)
---
Operating Margin
-317.78%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.